Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride (SUVN-911): A Novel, Potent, Selective and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.

Clicks: 184
ID: 92791
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #74 of 122 articles by views in Journal of medicinal chemistry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
A series of chemical optimizations guided by in vitro affinity at α4β2 receptor in combination with selectivity against α3β4 receptor, pharmacokinetic evaluation and in vivo efficacy in forced swim test resulted in identification of 3-(6-chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride (9h, SUVN-911) as a clinical candidate. Compound 9h is a potent α4β2 receptor ligand with Ki value of 1.5 nM. It showed >10 µM binding affinity towards ganglionic α3β4 receptor apart from showing selectivity over 70 other targets. It is orally bioavailable and showed good brain penetration in rats. Marked antidepressant activity and dose dependent receptor occupancy in rats supports its potential therapeutic utility in the treatment of depression. It does not affect the locomotor activity at doses several folds higher than its efficacy dose. It is devoid of cardiovascular and gastrointestinal side effects. Successful long term safety studies in animals and Phase-1 evaluation in healthy humans for safety, tolerability and pharmacokinetics paved the way for its further development.
Reference Key
nirogi2020discoveryjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nirogi, Ramakrishna;Mohammed, Abdul Rasheed;Shinde, Anil K;Ravella, Srinivasa Rao;Bogaraju, Narsimha;Subramanian, Ramkumar;Mekala, Venkat Reddy;Palacharla, Raghava Choudary;Muddana, Nageswararao;Thentu, Jagadeesh Babu;Bhyrapuneni, Gopinadh;Abraham, Renny;Jasti, Venkat;
Journal Journal of medicinal chemistry
Year 2020
DOI
10.1021/acs.jmedchem.9b00790
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.